Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA approves Novartis' once-yearly Reclast for postmenopausal osteoporosis

Aug. 20, 2007

CombinatoRx begins phase IIa study of CRx-401 for type 2 diabetes

Aug. 20, 2007

PTP-1B inhibitors claimed in recent patent by Metabasis

Aug. 20, 2007

AnGes submits Naglazyme BLA to Japanese Ministry of Health

Aug. 16, 2007

Roche and Schering-Plough separately claim novel compounds for obesity and related disordes

Aug. 16, 2007

Sosei completes phase I trial of emergency contraceptive pill NorLevo

Aug. 14, 2007

Patient treatment completed for BioDiem's phase I/II study of BDM-E

Aug. 14, 2007

Potential new treatments for obesity and psychiatric disorders patented by Athersys

Aug. 14, 2007

Phosphagenics cites positive phase Ib transdermal insulin clinical trial results

Aug. 13, 2007

Positive interim results for Genaera's phase I study of trodusquemine for obesity

Aug. 13, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...